The combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and safety as intravenous pertuzaumb and intravenous trastuzumab for HER2 positive breast cancer.
It is administered subcutaneously.
The fixed-dose combination of trastuzumab and pertuzumab offers a simpler, faster and easier treatment experience for patients with HER2-positive breast cancer.
The most common adverse effects for patients taking the fixed dose combination of pertuzumab, trastuzumab, and hyaluronidase were alopecia, nausea, diarrhea, anemia, and asthenia.